The Competition and Markets Authority (CMA) has issued fines as a result of their nortriptyline investigation. Nortriptyline is an unbranded, prescription-only generic medicine used for the relief of symptoms of depression. In some cases, it can be used to treat neuropathic pain and nocturnal enuresis (bed-wetting).
The CMA has recently issued decisions imposing fines on suppliers of nortriptyline tablets for reportedly breaching competition law after their nortriptyline investigation concluded. There have also been director disqualifications.
The Competition and Markets Authority (CMA) has launched an investigation into the supply of lithium-based medication, used to treat bipolar disorder.
The CMA has announced the investigation will look into prominent pharmaceutical company, Essential Pharma. They are suspected to have abused an alleged dominant position as a medication supplier by proposing to withdraw the supply of lithium-based medication to UK patients.
First published by Author on December 04, 2019 in the following categories: Healthcare Investigations Price Hikes and tagged with cma | competition law | drugs | investigations | Pharmaceuticals | pricing
The UK’s competition regulator has made a provisional finding in the longstanding investigation into drug price hikes, and the outcome is damning.
Issues surrounding pharmaceutical competition breaches are numerous and serious. At the end of the day, the consumer in these cases is patients and the NHS; that’s our tax money.
Any infringement of vital competition laws when it comes to medical matters should always lead to significant punishments, and the work of the CMA (Competition and Markets Authority) in this area is incredibly important. The provisional finding in this matter accompanies an admission from one of the companies involved as well.
Here’s the latest in the hydrocortisone tablets competition investigation that’s being conducted by the Competition and Markets Authority (CMA).
The history of this key study goes way back to October 2017 when the CMA started looking into alleged anti-competitive agreements and alleged abusive conduct. Exactly two years on, a great deal has happened as the CMA looks to ensure that the NHS and patients alike are not being ripped off by vastly wealthy pharmaceutical companies.
As we often say when the investigation involves the healthcare industry, this is a serious and important matter.
The deadline for continuing the Competition and Markets Authority (CMA) investigation into the privately funded healthcare services is looming.
The CMA has been looking into whether there’s any anti-competitive arrangements in the sector. If there are, competition may be stifled, and the consumer may be getting hit in the pocket.
When it comes to investigations that involve healthcare, they can often be the most important ones. They say that you can’t put a price on your health, but in reality, big medical companies and pharmaceutical giants literally do just that.